S2 E18.2 -- How Might We Treat Differently If We Knew Which Cirrhotic Patients Are Likely To Progress?
Send us Fan Mail The group focuses on the patient treatment implications of being able to identify the patients who are at risk of rapid progression, particularly among those with compensated cirrhosi...
10 Huhti 202123min
S2 E18.1 -- How Does MR Elastography Help Identify NASH PAtients Who Are Likely To Progress?
Send us Fan Mail Alina Allen shares the results of her recent Clinical Gastroenterology and Hepatology paper on predictive value of MR Elastography in determining likelihood of progress for NASH patie...
10 Huhti 202115min
S2-E18 - Magnetic Resonance Elastography Predicts Prognosis for NASH patients
Send us Fan Mail Alina Allen of the Mayo Clinic joins the Surfers to discuss her recent publication demonstrating that kPa scores from MR Elastography can predict the course of disease for non-cirrhot...
8 Huhti 20211h 9min
S2-E17.3 -- The value of ultrasound and the goals of patient screenin
Send us Fan Mail Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. This conversations starts by questioning the incremental v...
4 Huhti 202114min
S2-E17.2 — Modeling the relative impact of treating NASH vs. CVD in patients with different fibrosis levels
Send us Fan Mail Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversations to consider the goals for a t...
3 Huhti 202113min
S2-E17.1 - Questions in Screening: Do Liquid Tests Bring Better Value than Elastography?
Send us Fan Mail Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversation to consider what "efficiency" ...
3 Huhti 202120min
S2-E17 - New lessons from Leeds: Streamlining Non-Invasive Testing algorithms
Send us Fan Mail Ian Rowe joins the Surfers to discuss more detailed findings from the on-going analyses he and Richard Parker are conducting on abnormal liver tests among patients in Leeds, UK. In t...
1 Huhti 202158min
S2-E16.3 - How NASH treatment Might Evolve as Therapies Come to Market
Send us Fan Mail The final conversation of Episode 16 explores possible possible pathways and treatment strategies for NASH therapy in a future world with multiple classes of agents. In different wa...
28 Maalis 202116min
